# ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

- Source: PR Newswire
- Published: 2026-10-19T02:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/esmo-2026-preview--mabwell-to-present-clinical-results-for-nectin-4-targeting-adc-9mw2821-in-adc-pretreated-triple-negative-breast-cancer-302911988.html
- Canonical: https://groundlevelnews.com/story/esmo-2026-preview-mabwell-to-present-clinical-results-for-nectin-4-tar-923c3b/

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv")...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._